Using funds raised by our incredible community, we're proud to be launching the world’s largest prostate cancer and testicular cancer clinical and research network.
The Global Cancer Real World Evidence Network is aimed at improving the overall survival and quality of life for those living with the diseases that affect over 1.4 million men worldwide every year.
Over the next five years, we'll be investing up to $100 million AUD to establish the network which will fast-track the development and implementation of new tests, personalized treatments, and prostate cancer and testicular cancer quality and care programs.
The network is aiming to reach up to 500,000 men over the next five years through existing and new partnerships with over 600 hospitals in 19 countries*.
The ambitious initiative will build upon existing Movember-supported international programs across biomedical research, patient registries and survivorship to create what will be the most comprehensive and integrated prostate and testicular real world evidence network anywhere in the world.
For the first time, men across 19 countries will be given the choice of accessing and participating in an unprecedented portfolio of research and healthcare programs through one network.
By joining the network, men diagnosed and living with prostate cancer and testicular cancer will be given the choice to:
By building an integrated network of 500,000 men supporting research and real world implementation of innovative healthcare solutions, Movember will accelerate recruitment to clinical trials and the implementation of personalized healthcare to enable men to live longer, better quality lives.
Researchers and industry partners will be able to fast-track recruitment for clinical trials by identifying eligible patients at a global scale to understand which therapies, or combinations of therapies, deliver the best outcomes for patients in a real-world setting.
Existing and new clinical partners will collaborate with Movember to participate in clinical quality registries that support improvement in treatment and healthcare delivery.
In addition, the network will provide men and their families with access to personalized digital survivorship resources such as Movember’s True North program that supports men living with cancer during and after treatment. This enables them to manage the physical and mental side effects of living with cancer, as well as the long-term side effects of treatment.
The network will continue to support existing 400+ clinical partnerships that Movember has established through its existing programs and be significantly expanded through new clinical partnerships, with a particular focus on strengthening diversity in patient participation.
Over the coming weeks, Movember will announce the first of what will be a significant number of new research programs across biomedical research, clinical quality, and survivorship.
Paul Villanti, Executive Director of Programs at Movember, said: “Prostate cancer is the second most common cancer in men globally and testicular cancer is the most common cancer among young men. Almost 12 million men are estimated to be living with or beyond both diseases worldwide.
“Although tremendous progress has been made in recent years there is still much work to be done to further our understanding of which treatments work best for which men and reduce disparities in access to treatment and care.
“Establishing a global network that supports biomedical research, clinical trials, treatment quality improvement and personalized care for men is a major step forward. We can only truly accelerate improved health outcomes for men through global coordination and integration of biomedical research, clinical trials and improved treatment and care.”
Learn more about how Movember fundraising is fuelling groundbreaking men's health projects and research around the globe at movember.com/impact.
*Movember-supported registries currently cover Australia, Canada, Ireland, New Zealand, USA, United Kingdom, Germany, Spain, Sweden, Norway, South Africa, Switzerland, Czech Republic, Italy, Netherlands, Singapore, Hong Kong. The network will be expanded to include Denmark and France.